← Patent-cliff monitor small molecule TIBSOVO IVOSIDENIB
Loss of exclusivity June 2039 latest FDA-listed patent expiry
Company SERVIER PHARMACEUTICALS LLC
Drug detail Brand name TIBSOVO Active ingredient IVOSIDENIB Strength 250MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval July 2018 Marketing status RX
Listed patents Patent Expires Type 10980788 June 2039 use U-3113 10653710 October 2036 use U-3387 9968595 March 2035 product 10799490 March 2035 product 10449184 March 2035 product 9474779 August 2033 substance, product 10717764 January 2033 use U-3215 9850277 January 2033 substance, product 11667673 January 2033 use U-3742 10610125 June 2030 use U-3385
Regulatory exclusivity Code Expires ODE-447 October 2030 ODE-368 August 2028 I-924 October 2026 ODE-242 May 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.